As of today (2026-07-06), the Trailing Annual Dividend Yield of CASI Pharmaceuticals is 0.00%.
The historical rank and industry rank for CASI Pharmaceuticals's Dividend Yield % or its related term are showing as below:
FRA:ENM's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.43 * Ranked among companies with meaningful Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
CASI Pharmaceuticals (FRA:ENM) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
CASI Pharmaceuticals Dividend Yield % Related Terms
CASI Pharmaceuticals Dividend Yield % Historical Data
* Premium members only.
The historical data trend for CASI Pharmaceuticals's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:ENM vs ITRMF, OGEN, AZTR: Dividend Yield % Comparison
For the Biotechnology subindustry, CASI Pharmaceuticals's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CASI Pharmaceuticals Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where CASI Pharmaceuticals's Dividend Yield % falls into.
CASI Pharmaceuticals (FRA:ENM) has a Dividend Yield % of 0.00% as of Jul. 06, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on CASI Pharmaceuticals and its competitors. According to the industry distribution chart, CASI Pharmaceuticals ranks #999999 out of 153 companies in the Biotechnology industry.
Is CASI Pharmaceuticals' Dividend Yield % too high?
CASI Pharmaceuticals' current Dividend Yield % is 0.00%. Based on the distribution chart, CASI Pharmaceuticals ranks #999999 out of 153 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CASI Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does CASI Pharmaceuticals' Dividend Yield % compare to ITRMF and OGEN?
According to the Biotechnology industry distribution chart, CASI Pharmaceuticals ranks #999999 out of 153 companies for Dividend Yield %. This places CASI Pharmaceuticals in the lower half of its industry. The industry median Dividend Yield % is 1.43. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Biotechnology company?
The median Dividend Yield % among Biotechnology companies is 1.43, based on 153 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on CASI Pharmaceuticals and its competitors. For the Biotechnology industry, the median Dividend Yield % is 1.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CASI Pharmaceuticals's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CASI Pharmaceuticals stock overvalued right now?
CASI Pharmaceuticals (FRA:ENM) has a current Dividend Yield % of 0.00%. The stock's GF Value™ is €11.74, compared to a current price of €1.54 — trading 86.9% below its estimated fair value. The current Dividend Yield % is 0.00%. CASI Pharmaceuticals' overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For CASI Pharmaceuticals (FRA:ENM), the current Dividend Yield % is 0.00% as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CASI Pharmaceuticals (FRA:ENM) Overvalued in 2026?
Based on GuruFocus' analysis, CASI Pharmaceuticals stock appears to be undervalued.
The current stock price of €1.54 is trading 86.9% below its estimated GF Value™ of €11.74.
Key valuation signals for FRA:ENM:
Dividend Yield %: 0.00%
GF Value™: €11.74 vs. price of €1.54 (86.9% below fair value)
No single metric tells the full story. See the FRA:ENM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.
29GF Score
Get the complete analysis for FRA:ENM
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ENM has been successfully added to your 
